M&A law is the body of legal rules that governs how companies buy, sell, and combine with each other. It is not a single statute. It pulls from corporate law, securities regulation, antitrust enforcement, contract principles, and tax rules, and those overlapping disciplines together protect shareholders, keep markets competitive, and give buyers and sellers enforceable rights across what is usually a months-long transaction.
Because so many fields converge, the practice is structural: lawyers choose a deal form, then layer the regulatory, disclosure, and contract rules that form demands. The sections below walk through the choices and rules in the order they usually come up.
The Deal Structures M&A Law Treats Differently
The label “M&A” covers several distinct structures, and the choice drives nearly every legal and tax decision that follows.
A merger combines two companies into one. Either both dissolve and form something new, or one absorbs the other and the absorbed company ceases to exist. The survivor inherits everything: assets, contracts, employees, and liabilities. The disappearing company’s shareholders have to approve, so mergers come with formal votes and detailed disclosure documents.
A stock purchase works differently. The buyer purchases the target’s shares directly from its shareholders. The target stays intact as a legal entity; ownership changes hands. The buyer inherits every asset and every liability the company carries, including obligations that may not surface for years. That is why pre-closing investigation matters so much.
An asset purchase lets the buyer pick specific assets and leave unwanted liabilities behind. A manufacturer might buy another company’s equipment and customer contracts but decline to assume its pending lawsuits. The tradeoff is complexity: each contract being transferred may require the counterparty’s consent, and each asset may need its own transfer paperwork.
Tax treatment pulls the two sides in opposite directions. Sellers in a stock deal generally pay capital gains tax at long-term rates on the gain from their shares. Buyers often prefer asset purchases because they can “step up” the tax basis of the purchased assets and claim higher depreciation deductions going forward. This tension often becomes a core negotiating point.
A reverse triangular merger has become one of the most popular structures for larger deals because it borrows advantages from both. The buyer creates a temporary subsidiary that merges into the target. The subsidiary disappears, but the target survives as a wholly owned subsidiary of the buyer. The target’s contracts, licenses, and brand are preserved, many third-party consent requirements fall away, and the target’s pre-closing liabilities stay walled off inside the subsidiary. It also usually avoids a buyer shareholder vote, which speeds things up.
How a Deal Moves From First Conversation to Closing
Most acquisitions follow a recognizable sequence. Knowing the stages makes the legal documents easier to place.
A non-disclosure agreement comes first, signed before any sensitive information changes hands. It protects financial records, business strategies, and proprietary data exchanged during early talks. Without it, a potential buyer could walk away armed with the target’s trade secrets.
If early discussions go well, the parties sign a letter of intent or term sheet. It lays out the proposed price, payment structure, and major conditions, but most of its terms are non-binding. The portions that do bind usually cover exclusivity, which gives the buyer a window to investigate without competing bidders, and confidentiality.
The LOI opens the door to due diligence, the deep investigation of the target’s business. Once both sides are satisfied, they negotiate and sign a definitive agreement, either a stock purchase agreement, asset purchase agreement, or merger agreement, depending on structure. This is the binding contract that fixes the price, allocates risk, and spells out every obligation through closing.
Between signing and closing, the parties work through remaining conditions: regulatory approvals, shareholder votes, third-party consents, financing. Closing itself is often anticlimactic. Signatures exchange, funds move, ownership changes.
Due Diligence Is Where Deals Live or Die
Due diligence is the buyer’s chance to verify everything the seller has said about the business. Skipping or rushing it is where most acquisition disasters start. Several categories usually run in parallel.
Financial due diligence examines revenue, expenses, debts, and projections. Buyers look for accounting inconsistencies, undisclosed obligations, and whether reported earnings reflect repeatable performance rather than one-time gains.
Legal due diligence reviews corporate records, pending and threatened litigation, material contracts, regulatory compliance history, and organizational documents. The buyer’s lawyers want to know whether the company’s contracts will survive the transaction, whether any lawsuit poses meaningful exposure, and whether the company has been operating within the law.
Environmental due diligence matters whenever real property is involved. A Phase I Environmental Site Assessment, conducted under the ASTM E1527-21 standard, evaluates whether the property has contamination issues that could trigger cleanup liability under federal environmental law. It must be performed by an environmental professional and is generally valid for 180 days before the acquisition date. Skip it, and the buyer can be left responsible for millions in remediation costs.
Cybersecurity and data privacy diligence has become central. Buyers examine the target’s data collection practices, access controls, encryption standards, vulnerability testing, and compliance with privacy regulations. A data breach buried in the target’s systems can become the buyer’s problem the moment the deal closes.
Intellectual property diligence verifies that the target actually owns or properly licenses its patents, trademarks, copyrights, and trade secrets. For technology and life sciences companies, IP often represents the majority of the purchase price. Discovering after closing that a key patent is unenforceable, or that the company has been infringing someone else’s rights, can destroy the deal’s value.
The Contract Terms That Allocate Risk
The definitive agreement contains several mechanisms that decide who pays when something goes wrong. These provisions often matter more after closing than at signing.
Representations, Warranties, and Indemnification
Representations and warranties are factual statements each party makes about itself and the business. The seller might represent that its financial statements are accurate, that it has no undisclosed liabilities, and that it owns the intellectual property it claims to own. The buyer typically represents that it has the authority and financing to close. If any of these statements turn out to be false, the indemnification provisions decide who pays for the resulting losses.
Indemnification terms set limits on that exposure. A cap restricts the maximum the seller can be required to pay for breaches, often set as a percentage of the purchase price. A basket establishes a minimum threshold of losses before indemnification kicks in. In a deductible-style basket, the seller only pays for losses above the threshold. In a tipping basket, once losses cross the minimum, the seller is responsible for the entire amount from the first dollar. The deductible structure is more common.
Material Adverse Change Clauses
A material adverse change clause, sometimes called a material adverse effect clause, gives the buyer the right to walk away before closing if something significantly harmful happens to the target’s business. It is one of the most heavily negotiated provisions in any acquisition agreement. The seller wants narrow language that excludes broad economic downturns, industry-wide problems, and changes in law. The buyer wants language broad enough to cover any development that materially damages what it agreed to buy. How “material” gets defined can decide whether a buyer is locked into a deal that no longer makes economic sense.
Earn-Outs
When buyer and seller disagree on value, an earn-out can bridge the gap. The seller receives part of the purchase price upfront and earns additional payments if the business hits specified performance targets after closing. Revenue is the most commonly used metric, followed by earnings-based measures like EBITDA. Outside the life sciences sector, earn-out payments typically represent roughly a third of closing payments, with performance periods around 24 months. Life sciences deals tend to have larger earn-outs relative to closing payments, with longer measurement periods of three to five years tied to milestones such as regulatory approvals or clinical trial results.
Earn-outs create their own disputes. The buyer controls the business after closing, and the seller worries the buyer will make decisions that suppress the metrics the earn-out depends on. Courts have held that buyers exercising post-closing control are still bound by an implied obligation of good faith, meaning they cannot deliberately tank performance to avoid earn-out payments. Careful drafting of operational covenants and dispute resolution mechanisms is where experienced M&A lawyers earn their fees.
Representations and Warranties Insurance
Representations and warranties insurance has become standard in private acquisitions. Instead of relying only on the seller’s indemnity, the buyer purchases a policy that covers losses from breaches of the seller’s representations. The vast majority of these policies are buy-side.
Coverage limits typically run around 10% of transaction value, with premiums in the range of 2% to 3% of the coverage limit as a one-time payment for a multi-year policy. The policy carries a retention, functioning like a deductible, that usually starts at 0.75% of the deal value and may drop after the first year. R&W insurance does not cover everything. Standard exclusions include issues the buyer knew about before closing, forward-looking projections, pension underfunding, and deal-specific risks identified during underwriting. The insurance lets sellers walk away with cleaner proceeds while giving buyers a deeper pocket to recover from if problems surface.
Antitrust Review and the HSR Act
Federal antitrust law exists to prevent mergers that eliminate competition and harm consumers. Three statutes form the foundation. The Sherman Act prohibits contracts, combinations, and conspiracies that restrain trade, and makes monopolization a felony punishable by fines up to $100 million for corporations or $1 million for individuals. The Clayton Act targets acquisitions where the effect “may be substantially to lessen competition, or to tend to create a monopoly.” The FTC Act declares unfair methods of competition unlawful and empowers the Federal Trade Commission to enforce that prohibition.
The Hart-Scott-Rodino Act requires parties to certain deals to notify both the FTC and the Department of Justice before closing and then wait while regulators evaluate whether the transaction raises competitive concerns. The standard waiting period is 30 days from the date both parties’ filings are received, though cash tender offers get a shorter 15-day window. Regulators can extend the review by issuing a “second request” for additional information, which can add months.
Not every deal triggers an HSR filing. The 2026 minimum size-of-transaction threshold is $133.9 million, so transactions below that value are generally exempt. Additional thresholds apply based on the size of the parties involved. Filing fees scale with deal size, running from $35,000 for the smallest reportable transactions up to $2.46 million for transactions of $5.869 billion or more, and the thresholds and fees are adjusted annually for inflation. If regulators decide a deal would substantially lessen competition, they can go to court to block it.
Securities Law When a Public Company Is Involved
When publicly traded companies are part of a deal, federal securities law adds significant disclosure obligations designed to protect investors.
The Securities Act of 1933 requires companies to register securities offerings with the SEC so investors receive the financial and other significant information they need to make informed decisions. The Securities Exchange Act of 1934 governs ongoing disclosure for public companies, including Form 8-K current reports when material events occur. M&A transactions are among the events that trigger an 8-K filing, which must be submitted promptly.
When a merger or acquisition requires a shareholder vote, the company must file a proxy statement under the Exchange Act’s proxy solicitation rules. The proxy statement gives shareholders detailed information about the proposed transaction: its terms, the board’s recommendation, any fairness opinions obtained, and potential conflicts of interest among directors or officers.
Tender offers get their own layer. A tender offer is a public bid to buy shares directly from a company’s shareholders, often used in hostile acquisitions where the target’s board has not agreed to the deal. The Williams Act, enacted as amendments to the Securities Exchange Act, requires anyone making a tender offer that would give them more than 5% of a company’s shares to file a detailed disclosure statement (Schedule TO) with the SEC, deliver it to the target, and disseminate it to shareholders. The offer must stay open for a minimum period, giving shareholders time to evaluate the terms.
If the Buyer Is Foreign: CFIUS Review
When a foreign buyer acquires a U.S. business, the deal may face national security scrutiny from the Committee on Foreign Investment in the United States. Under the Foreign Investment Risk Review Modernization Act, CFIUS can review any transaction that could result in foreign control of a U.S. business. Certain filings are mandatory: deals where a foreign government acquires a “substantial interest” in specified types of U.S. businesses, and transactions involving U.S. companies that produce, design, test, or manufacture critical technologies. CFIUS can impose conditions, require changes to the structure, or recommend that the President block or unwind the acquisition entirely. Foreign acquirers who skip a required filing face real enforcement risk, because CFIUS can review completed transactions retroactively. The regime is specific to foreign acquirers and does not apply to domestic deals.
What Shareholders Can Do
Shareholders are not passive bystanders in M&A. State corporate law and equitable principles give them tools to protect their interests.
Fiduciary Duties of Directors
A company’s board owes fiduciary duties to its shareholders, including the duty of care and the duty of loyalty. In an M&A context, these duties require directors to make informed decisions about whether to approve a transaction, negotiate for the best available price, and avoid conflicts of interest. When shareholders allege the board breached these duties, courts typically start with a presumption that the directors acted properly, the business judgment rule. But that presumption can be rebutted. If directors appear to have approved a merger to extinguish derivative claims against themselves, or if a controlling shareholder pushed a deal through at an unfair price, courts can apply a more demanding “entire fairness” standard that scrutinizes both process and price.
Appraisal Rights
Most states give shareholders who oppose a merger the right to demand a court-determined “fair value” for their shares instead of accepting the merger consideration. This is called the right of appraisal, or dissenters’ rights. A shareholder who wants to exercise this right typically must not vote in favor of the merger, must make a written demand for appraisal before or shortly after the vote, and must hold the shares continuously through the merger’s effective date. A court then determines fair value, which may be higher or lower than the merger price. Appraisal rights exist under the corporate statutes of nearly every state, though procedures, deadlines, and exceptions vary. Review the specific rules of the state where the company is incorporated before relying on this right, because missing a procedural step can forfeit it entirely.
Tax, Employment, and IP Touchpoints
Tax law heavily influences how deals get structured. In a stock purchase, the selling shareholders recognize gain on the sale of their shares, taxed at long-term capital gains rates if the shares were held for more than a year. In an asset purchase, the buyer can allocate the purchase price among the acquired assets and depreciate them based on their stepped-up fair market value, generating tax deductions that reduce the effective cost of the acquisition over time. Some transactions can be structured as tax-free reorganizations, where the target’s shareholders receive stock in the acquiring company and defer recognizing gain until they eventually sell those shares. The choice between taxable and tax-free structures is one of the earliest and most consequential decisions in any deal.
Acquisitions frequently reshape the workforce, and federal law imposes notice requirements. The Worker Adjustment and Retraining Notification Act requires employers with 100 or more employees to provide at least 60 days’ advance written notice before plant closings or mass layoffs. Failing to give notice can create back pay liability to each affected employee for up to 60 days. Buyers and sellers have to coordinate carefully around closing to make sure WARN obligations are met, particularly in asset purchases where the seller’s employees may not automatically transfer to the buyer.
Intellectual property deserves its own look even outside due diligence. In asset purchases, IP rights must be specifically identified and transferred. In stock deals, the IP stays with the company, but the buyer should verify that no change-of-control provisions in licensing agreements are triggered by the transaction. Anti-assignment clauses in existing customer, supplier, and landlord contracts can create the same kind of complication, especially in asset deals where each contract has to be individually transferred.
Underneath all of this sits ordinary contract law. The definitive agreement has to be enforceable, and courts will hold parties to what they negotiated. Many acquisition agreements include specific performance provisions, meaning a court can order a reluctant party to close rather than simply awarding monetary damages. That remedy matters in M&A, where the target’s shareholders may have no adequate substitute for the deal they voted to approve.